December 5, 2024 03:03 PM EST
Pharma
FDA+

FDA spells out new ex­pe­dit­ed with­draw­al pro­ce­dures for ac­cel­er­at­ed ap­provals

Zachary Brennan

Senior Editor

The FDA on Thurs­day re­leased new de­tails on how it plans to ex­pe­dite the with­draw­al of cer­tain ac­cel­er­at­ed ap­provals when drugs fail to show clin­i­cal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J's new can­cer com­bo beats As­traZeneca's Tagris­so on sur­vival in lung tri­al

FDA sets an ef­fi­ca­cy thresh­old for fu­ture weight loss drugs

Sanofi part­ners with Al­loy Ther­a­peu­tics to make new CNS drug

Cal­i­co, De­nal­i's ALS drugs miss pri­ma­ry ob­jec­tives in bas­ket study

Ver­tex signs in vi­vo gene edit­ing de­liv­ery pact for sick­le cell and tha­lassemia as it looks be­yond Cas­gevy

Maze files for first biotech IPO of 2025, fol­low­ing $115M fund­ing boost

A service from the Financial Times